
Monday, March 8, 2010
Microfluidics adds two board members
By Mass High Tech staff
Microfluidics International Corp., a Newton-based manufacturer of fluid processors, has appointed Henry Kay and Stephen Robinson to its board of directors. Microfluidics’ (OTC:MFLU) Microfluidizer fluid processors are used for particle size reduction, nanoparticle creation and cell disruption by biotechnology, pharmaceutical, chemical, nutraceutical, cosmetic and energy companies.
Henry Kay works currently as U.S. partner of Medica Venture Partners of Israel. He previously served at Boston Scientific Corp. as group vice president of new market development and strategic planning, endosurgery. A fellow of the Royal Society of Medicine, Kay held previous roles at Schering-Plough, Allergan Europe and American Home Products. He graduated with a MBA in international marketing from Seton Hall University, a master’s of science degree from Rutgers University and a bachelor’s degree in chemistry from Augusta College.
Stephen Robinson serves currently as vice president, SAFC Hitech at Sigma Aldrich. He previously was CEO of chemical processors supplier Epichem Inc., which was bought by Sigma Aldrich in 2007. Robinson earned a bachelor of science degree in chemical engineering from the University of Leeds in the U.K.
The two new board members join Microfluidics’ current board of company president and CEO Michael Ferrara, board chairman George Uveges, Leo Pierre Roy and Eric Walters.
Microfluidics is involved in mixing vaccines with adjuvants — substances that may be added to the vaccines to make them work better.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.

Print
Email
Print Edition Stories



